Trials / Completed
CompletedNCT01548430
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
A Double-blind, Randomized, Placebo-controlled, Phase 1 Study of 2 Escalating, Single Subcutaneous Doses to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of TTP4000 in Subjects With Alzheimer's Disease With Mild Cognitive Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- vTv Therapeutics · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTP4000 | |
| DRUG | Placebo |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2012-03-08
- Last updated
- 2015-02-12
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01548430. Inclusion in this directory is not an endorsement.